Impact of antenatal antiretroviral drug exposure on the growth of children who are HIV‑exposed uninfected : the national South African Prevention of Mother to Child Evaluation cohort study

Please be advised that the site will be down for maintenance on Sunday, September 1, 2024, from 08:00 to 18:00, and again on Monday, September 2, 2024, from 08:00 to 09:00. We apologize for any inconvenience this may cause.

Show simple item record

dc.contributor.author Ramokolo, Vundli
dc.contributor.author Kuhn, Louise
dc.contributor.author Lombard, Carl
dc.contributor.author Jackson, Debra
dc.contributor.author Goga, Ameena Ebrahim
dc.date.accessioned 2023-04-28T11:33:48Z
dc.date.available 2023-04-28T11:33:48Z
dc.date.issued 2022-12-06
dc.description ADDITIONAL FILE 1: BOX 1. Anthropometry data cleaning criteria. FIGURE S1. Directed Acyclic Graph representing the hypothesized relationships, 2012–2014, South Africa. FIGURE S2. Study cohort profile of HIV exposed uninfected infants from 6-weeks to 18-months postpartum, 2012–2014, South Africa. TABLE S1. Proportion of underweight children from 6-weeks to 18-months postpartum by in-utero antiretroviral exposure status, 2012–2014, South Africa. TABLE S2. Proportion of stunted children from 6-weeks to 18-months postpartum by in-utero antiretroviral exposure status, 2012–2014, South Africa. TABLE S3. Frequency of maternal antiretroviral treatment over time by baseline maternal antiretroviral categories, 2012–2014, South Africa en_US
dc.description.abstract BACKGROUND : The relationship between in-utero antiretroviral (ARV) drug exposure and child growth needs further study as current data provide mixed messages. We compared postnatal growth in the first 18-months of life between children who are HIV-exposed uninfected (CHEU) with fetal exposure to ARV drugs (prophylaxis or triple-drug therapy (ART)) and CHEU not exposed to ARVs. We also examined other independent predictors of postnatal growth. METHODS : We analysed data from a national prospective cohort study of 2526 CHEU enrolled at 6-weeks and followed up 3-monthly till 18-months postpartum, between October 2012 and September 2014. Infant anthropometry was measured, and weight-for-age (WAZ) and length-for-age (LAZ) Z-scores calculated. Generalized estimation equation models were used to compare Z-scores between groups. RESULTS : Among 2526 CHEU, 617 (24.4%) were exposed to ART since -pregnancy (pre-conception ART), 782 (31.0%) to ART commencing post-conception, 879 (34.8%) to maternal ARV prophylaxis (Azidothymidine (AZT)), and 248 (9.8%) had no ARV exposure. In unadjusted analyses, preterm birth rates were higher among CHEU with no ARV exposure than in other groups. Adjusting for infant age, the mean WAZ profile was lower among CHEU exposed to preconception ART [-0.13 (95% confidence interval − 0.26; − 0.01)] than the referent AZT prophylaxis group; no differences in mean WAZ profiles were observed for the post-conception ART (− 0.05 (− 0.16; 0.07)), None (− 0.05 (− 0.26; 0.16)) and newly-infected (− 0.18 (− 0.48; 0.13)) groups. Mean LAZ profiles were similar across all groups. In multivariable analyses, mean WAZ and LAZ profiles for the ARV exposure groups were completely aligned. Several non-ARV factors including child, maternal, and socio-demographic factors independently predicted mean WAZ. These include child male (0.45 (0.35; 0.56)) versus female, higher maternal education grade 7–12 (0.28 (0.14; 0.42) and 12 + (0.36 (0.06; 0.66)) versus ≤ grade7, employment (0.16 (0.04; 0.28) versus unemployment, and household food security (0.17 (0.03; 0.31). Similar predictors were observed for mean LAZ.. CONCLUSION : Findings provide evidence for initiating all pregnant women living with HIV on ART as fetal exposure had no demonstrable adverse effects on postnatal growth. Several non-HIV-related maternal, child and socio-demographic factors were independently associated with growth, highlighting the need for multi-sectoral interventions. Longer-term monitoring of CHEU children is recommended. en_US
dc.description.department Paediatrics and Child Health en_US
dc.description.librarian am2023 en_US
dc.description.sponsorship US President’s Emergency Plan for AIDS Relief (PEPFAR) through the Centers for Disease Control and Prevention under terms of cooperative Agreement, UNICEF, the South African Medical Research Council, the South African National AIDS Council, the National Institute of Communicable Diseases, the National Department of Health and the Global Fund and L’Oreal- UNESCO For Women in Science South African National Young Talents Award. en_US
dc.description.uri http://www.biomedcentral.com/bmcinfectdis en_US
dc.identifier.citation Ramokolo, V., Kuhn, L., Lombard, C. et al. 2022, 'Impact of antenatal antiretroviral drug exposure on the growth of children who are HIV‑exposed uninfected : the national South African prevention of mother to child evaluation cohort study', BMC Infectious Diseases, vol. 22, art. 908, pp. 1-14, doi : 10.1186/s12879-022-07847-9. en_US
dc.identifier.issn 1471-2334 (online)
dc.identifier.other 10.1186/s12879-022-07847-9
dc.identifier.uri http://hdl.handle.net/2263/90535
dc.language.iso en en_US
dc.publisher BMC en_US
dc.rights © The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License. en_US
dc.subject HIV-exposed uninfected en_US
dc.subject Postnatal growth en_US
dc.subject Children en_US
dc.subject Human immunodeficiency virus (HIV) en_US
dc.subject Antiretroviral (ARV) en_US
dc.subject Children who are HIV-exposed uninfected (CHEU) en_US
dc.subject Mother-to-child transmission (MTCT) en_US
dc.title Impact of antenatal antiretroviral drug exposure on the growth of children who are HIV‑exposed uninfected : the national South African Prevention of Mother to Child Evaluation cohort study en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record